[Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
There is a disclosure of the results of the therapy of gastroesophageal reflux disease at the stage of reflux esophagitis with gastrosidin (famotidine), 40 mg twice a day during 4-8 weeks. The dosage of gastrosidin (famotidine) was reduced to 40 mg a day only if side effects appeared: diarrhea (4) and urticaria (3). After four weeks of treatment, endoscopic symptoms of esophagitis disappeared in 17 patients out of 28 (60.7%), and a positive dynamics was recorded in 11 patients. After eight weeks of treatment, the disappearance of endoscopic symptoms of esophagitis was recorded in 7 patients out of 8 (including the healing of the peptic esophagus ulcer in one patient). Three patients (who were feeling good) refused to undergo a control endoscopic examination.
Vasil'ev
Iu V
IuV
Central Scientific Research Institute of Gastroenterology, Moscow.
Li
I A
IA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D015738:Famotidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005764:Gastroesophageal Reflux / Q000209:etiology / Q000517:prevention & control*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D015738:Famotidine